Abivax SA’s American depositary shares are trading higher as investors react to newly available preparatory documents for the company’s Annual Ordinary and Extraordinary General Meeting scheduled for May 11, 2026 in Paris. The meeting notice and draft resolutions include standard annual approvals (2025 accounts) alongside corporate actions such as authorization for the board to repurchase shares and the ability to cancel treasury shares, which can support sentiment in a momentum-driven biotech tape. (ir.abivax.com)

While shareholder-meeting paperwork is typically routine, ABVX has been trading as a catalyst stock since its late-stage ulcerative colitis program advanced, so incremental corporate signals can drive flows. The agenda’s inclusion of buyback-related authorizations can be interpreted as financial flexibility and optionality, even if execution depends on future board decisions and market conditions. (marketscreener.com)

Beyond the meeting, attention remains on Abivax’s 2026 roadmap for obefazimod (ABX464) in inflammatory bowel disease, with the company outlining ongoing Phase 3 work and a late-Q2 2026 timeframe for key progress in its ulcerative colitis program. With ABVX prone to outsized moves around development milestones, traders often re-price the stock on any calendar item that tightens the path to the next readout. (ir.abivax.com)